Sunday, 31 August 2008

PolyMedix Initiates Dosing In Phase I Clinical Study Of Novel Systemic Antibiotic Compound

�PolyMedix, Inc. (OTC BB: PYMX), an emerging biotech company developing new therapeutical drug products to treat infectious diseases and penetrating cardiovascular disorders based on biomimetics, has initiated dosing and commenced a Phase I clinical study in Canada for its defensin mimetic antibiotic compound, PMX-30063. PolyMedix received a notice of no objection from Health Canada for the Company's Clinical Trial Application ("CTA") for PMX-30063 in May 2008. PMX-30063 is the first gear and only defensin mimetic antibiotic compound to enter human clinical trials for systemic habit, and represents an entirely new class of antibiotic drugs.


This first Phase I clinical trial testament assess the safety of PMX-30063. The protocol for the trial involves a dose-escalation written report in healthy volunteers in which each subject testament receive a single dose of PMX-30063. The subjects are grouped into different cohorts with different dosage levels which will admit for the study of the effects of increased dosages. PolyMedix expects to enroll a total of thirty to fifty subjects in this clinical tribulation. Upon successful completion of the first-class honours degree clinical subject area, PolyMedix plans to initiate a second clinical trial run to mimic the expected clinical dosing regimen. The second run, also to be conducted in healthy volunteers, will involve iterate dosing of two endovenous infusions per day, for up fourteen days. Following these clinical trials, meaning additional clinical studies and regulatory submissions will be required to obtain regulative approval from the FDA and other regulatory bodies before PMX-30063 could be commercially sold.


"The commence of the clinical survey for PMX-30063 represents a major milestone for PolyMedix, and we believe, for the full medical community of interests," said Nicholas Landekic, CEO of PolyMedix. "This novel antibiotic combine signals a fundamental potential breakthrough in treating infectious diseases. PMX-30063 is the first and only modest molecule defensin mimetic to commence clinical development for the treatment of systemic infections, and the first and solely such compound whose mechanism of action mechanism is intended to straight address the major problem of bacterial drug resistance. We ar proud to be the first troupe to bring this completely new type of antibiotic drug to clinical trials, and to address a major clinical want and market opportunity."

About PMX-30063


Completely different from other antibiotic drug compounds currently on the market, PMX-30063 is a synthetic chemical mimic of host united States Department of Defense proteins, one of the oldest and most in force antimicrobial defense systems ground in well-nigh all living creatures. PMX-30063 is the first little molecule mimetic of host defense proteins to embark clinical trials intended to treat systemic infections.


PolyMedix has undertaken in vivo studies in animals and in vitro pre-clinical studies to observe compound efficacy and toxicology attributes, and to judge the development of drug resistance. Based on these pre-clinical studies, we believe PMX-30063 has unique properties which sets it apart from traditional antimicrobial molecules and materials, including:


- A novel mechanism of action, the aim biophysical disruption of bacterial cell membranes, that makes development of bacterial resistance unlikely;


- Activity against both Gram-positive and Gram- minus bacteria, and in especial, activity against 146 dissimilar strains of Staphylococcus bacterium, including 89 drug-resistant strains of Staph bacteria;


- Bactericidal activity, meaning it kills bacteria directly, rather than simply stopping reproduction (bacteriostatic) as do many current antibiotics;
- Faster acting than many antibiotics; and


- Activity against drug-resistant bacteria, including clinical isolates of multiple vancomycin- and methicillin-resistant strains.


Primitive life sentence forms, such as molds, secrete compounds like penicillin to protect themselves from bacteria. This forms the basis for conventional antibiotics - compounds which act against biochemical targets or pathways in bacterial cells. Multi-cellular organisms, such as insects, animals, and human race, possess a more complex, first-line immune system defence against bacterial infections: the host defence proteins. Host defense proteins are part of the non-humoral (that is, not involving antibodies) response that keep world from speedily succumbing to infections. Biologists have observed many different classes of natural host-defense peptides. Although these molecules possess a diverse array of structures, their physicochemical properties ar similar. All are amphiphilic, meaning they have a combination of positively electrically charged properties, and hydrophobic (water-hating, fat-loving) chemical properties. This amphiphilic structure is believed to be responsible for horde defense peptides' antimicrobial activity and their unique abilities to straight disrupt bacterial cell membranes. Among the most vulgar and well-studied antimicrobial peptides are the defensins, establish in human beings, the magainins, found in frogs, and the cecropins and melitins, found in insects.


PMX-30063 is designed to mimicker the amphiphilic structure of the host defense proteins, but with a completely synthetic, non-peptide, small corpuscle structure. PMX-30063 directly disrupts bacterial electric cell membranes; a mechanism shared with the host defence proteins just is unique among known antibiotic drugs. For this reason, we believe that bacterial opposition is less likely to develop with PMX-30063 than has been experienced with many conventional antibiotic drugs. Multiple serial passage experiments conducted by PolyMedix and others on PMX-30063 and related PolyMedix antibiotic compounds also support our view of a lower likeliness of developing resistance.

About PolyMedix, Inc.


PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of infectious diseases and sharp cardiovascular disorders. PolyMedix's compounds are based on biomimetics: non-peptide small molecule drugs that mimic the activity of proteins. The Company's antibiotic compounds, including PMX-30063 - small molecule mimetics of human host-defense proteins - have a wholly different mechanism of activity from stream antibiotic drugs, a mechanism which is intended to make bacterial resistance improbable to develop. These compounds are organism developed as rapidly performing antibiotics for serious systemic and local infections. The Company plans to go on the development of polymeric formulations as antimicrobial biomaterials, which canful be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces. The Company's heptagonist compounds, including PMX-60056, reverse the activity of both heparin and Low Molecular Weight Heparins, with the goal of developing an antagonist drug that is safer and easier to use than currently sanctioned therapy. For more information, please visit PolyMedix on its web site at hTTP://www.polymedix.com.


This press release contains advanced statements made pursuant to the good harbor victuals of the Private Securities Litigation Reform Act of 1995 that involve risks and that could reason PolyMedix's actual results and experience to differ materially from awaited results and expectations expressed in these forward looking for statements. PolyMedix has in some cases identified forward-looking statements by using language such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends" and similar expression.. Among other things, there can buoy be no assurance that PolyMedix's compounds will enter or successfully complete clinical testing or be given regulatory approval to be sold and marketed in the Unites States or elsewhere. A more complete description of these risks, uncertainties and assumptions is included in PolyMedix's filings with the Securities and Exchange Commission. You should t stead undue reliance on any forward-looking statements. PolyMedix undertakes no duty to release publicly the results of any revisions to any such innovative statements that may be made to reflect events or luck after the date of this crusade release or to reflect the occurrence of unforeseen events.

PolyMedix, Inc.


More information
Posted by at

Monday, 11 August 2008

Blige Sued In Song Row

R+B star MARY J. BLIGE has been accused of theft songs from a California hip-hop tag in a new cause filed on Wednesday (06Aug08).


Drama Family Entertainment bosses claim Blige's hit single Work That was taken from their catalogue of songs.


It is alleged they hired producer Theron Feemster to record hits for their own artists - only instead he gave tracks to Blige.


The production company and record label executives claim Feemster's sung Pull 1 Rough, created during his time with Drama Family, very closely resembles Blige's single from her 2007 album Growing Pains - featured in an Apple iPod commercial-grade.


The company's lawyer Brian Caplan adds, "The music is identical."


The singer's bosses at Interscope Geffen - which has besides been named in the suit - have refused to remark, insisting they never discourse pending litigation.


Lawyers for Blige and Feemster did not return calls for comment.











More information
Posted by at

Wednesday, 6 August 2008

The Latest On Premier Science In Medical Oncology At The 33rd ESMO Congress, Stockholm, Sweden, Sept. 12-16, 2008

�Congress Highlights





Some of the highlights that will be presented during the educational and scientific program at Europe's prime minister medical oncology meeting include:
Molecular analysis for target discovery: Identification of 'Achilles' heel'


MicroRNa, SiRNA libraries


Protein array





Innovation in titty cancer


Modulation of resistance to anti-Her2 therapies


Evaluation of prognostic markers on circulating tumour cells


New targets for three-bagger negative tumors


Stem cell as a potency target


Tools in daily clinical practice to improve treatment





Tailoring therapy in lung cancer


Medical implications of resistance to EGFR


Personalized cancer therapies for non-EGFR receptor-dependent tumors





New pathways in targeted therapy


IGF-1, PI 3, PARP, Met





Optimal integration of newer agents in the treatment of advanced CRC


Genomic and pharmacogenetic markers for treatment decision


Upfront serial vs. combination chemotherapy





Renal cell cancer


VEGF biology and resistance


mTOR


Tackling future issues





Hitting the cell in ovarian and endometrial cancers


PARP, mTOR, etc





Head and neck cancer


Viruses: Prevention and therapy


Innovations in radiation oncology (IMRT and look-alike guided radiotherapy)


How to integrate EGFR inhibitors and beyond





Hematological malignancies


The role of high-dose therapy and allografting stemcell transplanting in the era of '-nibs' and '-mabs'





Communication skills in advanced crab care
o The use of communication skills: Lessons derived from microanalytical studies





Advances in soft tissue sarcoma, GIST and beyond


GIST - the role of adjuvant therapy and mutational analysis in treatment decision-making


Molecular biology and targeted therapy of sarcomas


Hyperthermia improves local control of STS - where future?





Emerging therapies for rare tumors


Neuroendocrine tumors, HCC, thyroid cancer, papillary RCC





Assessing, reporting and managing the safety of cancer drugs


Detecting safety signals


The function of pharmacogenetics in predicting and managing toxicity


Handling side effects of targeted therapies





Integration of targeted therapies with radiation


Where we are with radiation modifiers?





Unplanned analysis of molecular studies


Harmful or safe?





Cancer patients


o Should all receive prophylactically antithrombotic therapy?


o Dealing with hard cases in daily clinical practice






New developments in myeloma


Prognostic factors and the role of novel drugs


The status of transplantation





Glioma


From tomography to management





Recent progress in immunotherapy


Anti cancer vaccines


Combining immunotherapy with classical antineoplastic therapy





Advanced prostate genus Cancer


The ever-changing face of hormonal therapy


Diabetes and cardiovascular disease in prostate cancer survivors





Latest on oncology in developing countries


Cancer encumbrance and the role of prevention


Balancing costs and benefits in malignant neoplastic disease therapy and prevention





Drug development


How to recognize a promising drug: The role of clinical and biologic endpoints


The persona of regulatory bodies in the do drugs approval process


The Highlights of the day session: summary roger Huntington Sessions of topics from the preceding day aiming to give an overview of the to the highest degree interesting and important points to emerge from previous sessions.





Late-breaking abstracts: oral roger Huntington Sessions to represent latest research studies with new research findings





Controversy roger Sessions will make lively discussions on hot topics.





The seventh ESMO Patient Seminar where patients will have the chance to meet oncologists and hear about the conditions of cancer treatment in Europe, comparing conditions in Eastern and Western countries; discuss and face up doctors around the consequences of cancer the Crab therapy, instruct the approaches to long-term survivorship and the next perspective of cancer treatments





Numerous Educational Sessions to submit state-of-the-art oncology.





The fifth slew of ESMO Designated Centers of Integrated Oncology and Palliative Care will be announced as centers of excellence for patient precaution in Europe.





A session on ESMO Clinical Recommendations will update current ESMO Guidelines on clinical practice for various tumour types.





Oncology Highlights of the most significant advances in cancer handling in 2008.





And� Her Majesty Queen Silvia of Sweden accepted to be the Patron of the thirty-third ESMO Congress and will give the welcome address during the Opening Ceremony





Meeting venue





The 33rd ESMO Congress will take place at the Stockholm International Fairs in �lvsj� (M�ssv�gen 1, SE-12580 Stockholm-�lvsj� located a short train journey from Stockholm Central Station.





The conference full broadcast is usable at http://www.esmo.org/activities/esmocongress/stockholm08/program_cng/





Accomodation





Congrex Sweden AB has been appointed by ESMO to manage hotel accommodation in relation to the thirty-third ESMO Congress For hotel reservation, please visit: http://www.esmo.org/activities/esmocongress/stockholm08/accommodation_cng/









About the European Society for Medical Oncology (ESMO)





The European Society for Medical Oncology (ESMO) is the leading European not-for-profit, professional organisation for medical oncology promoting multidisciplinary malignant neoplastic disease treatment around the world.





ESMO unites aesculapian oncologists and other oncology specialists, healthcare professionals, caregivers, patients, policy-makers and all the key stakeholders in a world-wide alliance committed to eradicating cancer and ensuring equal access to high quality treatment for all patients. Through state of the art education and training programs, ESMO plays an subservient role in providing the oncology community with the most up-to-date scientific research and information available. ESMO is dedicated to educating and supporting oncologists, optimizing patient guardianship, disseminating cancer-specific information to the public, and advocating patient rights. As an authoritative part in the fight against cancer, ESMO provides both the platform and the consultative expertise to influence national and international organizations as well as European authorities, in order to establish common standards for a multidisciplinary approach to cancer treatment. Through its flagship daybook, Annals of Oncology, ESMO publishes articles on all aspects of clinical oncology.





To find kO'd more about ESMO please visit hTTP://www.esmo.org/





Source: Vanessa Pavinato



European Society for Medical Oncology




More info
Posted by at
Subscribe to: Posts (Atom)